

# Juan Miguel Cejalvo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6585453/publications.pdf>

Version: 2024-02-01

14  
papers

554  
citations

1039406

9  
h-index

1199166

12  
g-index

14  
all docs

14  
docs citations

14  
times ranked

545  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	2.3	331
2	Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7812.	1.8	64
3	Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 96-106.	2.0	41
4	Breast cancer in pregnant patients: A review of the literature. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2018, 230, 222-227.	0.5	23
5	Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. <i>Science Advances</i> , 2022, 8, .	4.7	21
6	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 69-77.	1.1	20
7	HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women. <i>Cancers</i> , 2020, 12, 412.	1.7	16
8	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021, 125, 1261-1269.	2.9	14
9	Fertility and breast cancer: A literature review of counseling, preservation options and outcomes. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103461.	2.0	10
10	Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015, 8, 1053.	1.0	6
11	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 1108-1121.	1.5	5
12	Immunological Landscape of HER-2 Positive Breast Cancer. <i>Cancers</i> , 2022, 14, 3167.	1.7	3
13	In the literature: June 2020. <i>ESMO Open</i> , 2020, 5, e000832.	2.0	0
14	In the literature: August 2020. <i>ESMO Open</i> , 2020, 5, e000909.	2.0	0